Introduction: Synapse loss is the basis of the cognitive decline indicative of dementia. In the brains of Alzheimer's disease (AD) sufferer's amyloid beta (Ab) peptides aggregate to form senile plaques but as soluble peptides that are toxic to synapses
Background
Amyloid beta (Ab) has long been associated with Alzheimer's disease (AD) through a propensity to form insoluble deposits, senile plaques, a hallmark of the AD brain. Overwhelming genetic and experimental evidence indicate that Ab and its parent molecule, the amyloid precursor Conflicts of interest: The authors have declared that no conflict of interest exists. 1 These authors contributed equally to this work. *Corresponding author. Tel.: 144-207-848-0139; Fax: ---.
protein (APP), are key players in the neuropathogenic processes driving AD
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. Ab readily self-associates to form a range of soluble oligomers and insoluble fibers, and the current consensus view holds that these are the small soluble oligomeric forms of Ab rather than the plaques themselves that are the neurotoxic species [1] [2] [3] . We have previously found that Ab-driven increases in tau phosphorylation (a second hallmark of the disease) and neuronal death are dependent on activation of a branch of Wingless/Wnt signaling known as the Wnt-planar cell polarity (Wnt-PCP) pathway, specifically the arm of Wnt-PCP acting through JNK and its target c-Jun to regulate gene transcription [4] . We have shown that Ab activates Wnt-PCP through the ability of Ab to induce Dickkopf-1 (Dkk1), which by blocking the binding interaction between LRP6 and frizzled prevents canonical Wnt-b-catenin activity and concomitantly activates Wnt-PCP signaling [5, 6] . Furthermore, our data indicate that Dkk1 and Wnt-PCP shape the transcriptomic profile of the AD brain and the activity of pathways within it most associated with the disease [4, 7] . The top four most significant of these pathways being the Adherens Junction, Wnt signaling, TGF-b signaling, and LTP, which are all intimately involved in synaptic plasticity Q6 [8] [9] [10] . Ab synaptotoxicity is thought to be a very early event in the disease process, central to disease etiology, and possibly the driver of many other neurotoxic properties attributed to Ab [2, 11, 12] . Indeed, the degree of cognitive impairment in AD correlates more closely with synapse number than with amyloid load or extent of tau pathology [2, 13, 14] . However, although widely studied, the underlying mechanisms of Ab synaptotoxicity have yet to be fully determined [2, 15] .
The synaptic effects of Ab have been reported to be Dkk1 dependent [16] . In addition to influencing transcription via JNK/c-Jun, the Wnt-PCP pathway also regulates cytoskeletal dynamics through ras homolog family member A (RhoA) and rho-associated coiled-coil containing protein kinase (ROCK), two key regulators of synapse formation [17, 18] , shown to be responsive to Ab [19] . Given this, we investigated the possibility that Ab may exert its synaptotoxicity by activating the Wnt-PCP/RhoA/ROCK pathway and present evidence that this is the case. Furthermore, we have evaluated the potential of the ROCK inhibitor drug, fasudil, as a therapeutic approach to ameliorate both the synaptic and cognitive effects of Ab.
Methods

Dkk1 measures
Rat Dkk1 messenger RNA expression was performed by quantitative RT-PCR and protein levels determined using a DuoSet enzyme-linked immunosorbent assay Kit (R&D Systems, DY1906), both as previously described
Neuronal culture and transfections
Primary cortical neuronal cultures were prepared from Sprague-Dawley rat E18 embryos as described previously [20] . Cells were seeded onto coverslips coated with poly-Dlysine (0.2 mg/mL, Sigma), at a density of 3 ! 10 5 /well equating to 857/mm 2 . Cells were cultured in feeding media: neurobasal medium (21103049) supplemented with 2% B27 (17504044), 0.5 mM glutamine (25030024), and 1% penicillin/streptomycin (15070063) (all reagents from Life technologies, UK). After 4 days in vitro (DIV) 200 mM D,L-aminophosphonovalerate (ab120004; Abcam) was added to media to maintain neuronal health over long-term culture and to reduce cell death because of excitotoxicity [20] . Fifty percent media changes were performed twice weekly until desired time in culture was reached (DIV 23). Cells were then transfected with an eGFP expression construct driven by the synapsin 1 promoter using Lipofectamine 2000
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. Transfections were allowed to proceed for 2 days, resulting in 5% to 10% transfection efficacy [20, 21] .
Pharmacologic treatments of neuronal cultures
All pharmacologic treatments were performed in artificial cerebral spinal fluid: 125 mM NaCl, 2.5 mM KCL, 26.2 mM NaHCO 3 , 1 mM NaH 2 PO 4 , 11 mM glucose, 5 mM Hepes, 2.5 mM CaCl 2, 1.25 mM MgCl 2 , and 0.2 mM aminophosphonovalerate. Neuronal cultures were pretreated with inhibitor compounds for 30 minutes before application of Dkk1 recombinant protein, Ab 1-42 oligomers (AbO), or fibrillar Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to culture media. All compounds were dissolved in water or DMSO at a concentration of 10 or 1 mM, and serially diluted to a 10 times working concentration in artificial cerebral spinal fluid and applied directly to neuronal cultures
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. Final concentration of solvent was ,0.01%, as also used in vehicle control. Treatments were allowed to proceed for indicated times before being fixed for immunocytochemistry.
Immunocytochemistry
Neurons were washed in phosphate-buffered saline and then fixed in either 4% formaldehyde/4% sucrose in phosphate-buffered saline for 10 minutes at room temperature followed by incubation in Q10 methanol prechilled to 220 C for 10 minutes at 4 C or in methanol (220 C) only for 20 minutes at 4 C. Fixed neurons were then permeabilized and blocked simultaneously (2% nonimmune goat serum, Sigma, and 0.2% Triton X-100) before incubation in primary antibodies overnight and subsequent incubation with secondary antibodies the following day [20] . In the green/purple color scheme, colocalization is indicated by white overlap.
Antibodies used
The following antibodies were used: GFP, chicken polyclonal (ab13972; Abcam); PSD95, mouse monoclonal (clone K28/43; 73-028; NeuroMab); PSD-95, rabbit polyclonal (2507; Cell Signaling Technology); Bassoon, mouse monoclonal (ab82958; Abcam); and GluA1, rabbit polyclonal (ABN241; Millipore Q11 ).
Spine morphology and immunofluorescence
Images were acquired with a Leica SP-5 confocal microscope using a 63! oil-immersion objective (Leica, N.A. 1.4) as z-series. Two-dimensional maximum projection reconstructions of images were generated, and morphometric analysis (spine number, area, and breadth) was performed using MetaMorph software (Universal Imaging Corporation, West Chester, PA, USA) [20] . Morphometric analysis was performed on spines from at least two dendrites (secondary or tertiary branches), totaling 100 mm in length, per neuron. For each condition, 9 to 12 neurons from at least three separate experiments (each performed in duplicate) were used. Experiments were carried out blind to condition. Linear density and total gray value of each synaptic protein cluster was measured automatically using MetaMorph [20] . Cultures undergoing direct comparison were stained simultaneously and imaged with the same acquisition parameters.
Pharmacodynamics
Fasudil and hydroxyfasudil were administered separately at 10, 30, and 100 mg/kg by intraperitoneal (IP) injection to young adult male CD1 mice. Animals were sacrificed 20 minutes after dosing and terminal plasma and brain samples were taken. Proteins were extracted using acetonitrile precipitation, and fasudil and hydroxyfasudil levels were measured by UHPLC-TOF mass spectrometry using electrospray ionization Q12 .
Behavioral testing
Animals
Female Lister Hooded rats (Charles River, UK; weighing w215 6 20 g at the start of experimentation) were housed in groups of five in individually ventilated two-story home cages, on a 12 hours light cycle (illuminated 07:00-19:00 hours) with controlled temperature (21 6 2 C) and humidity (55 6 5%). Water and food (Special Diet Services, UK) were given ad libitum. All experiments were undertaken during the illuminated period and conducted in accordance with UK Animals (Scientific Procedures) 1986 Act and the University of Manchester ethical guidelines.
AbO preparation
Biotin-Ab 1-42 (ANA24640) was purchased from Anaspec, USA, disaggregated in hexafluoroisopropanol for 1 hour, aliquoted, hexafluoroisopropanol removed by evaporation under N 2 , and monomeric peptide solublized in DMSO at 1 mM, diluted to 100 mM in Ham's F12, and allowed to oligomerize at room temperature for 16 hours.
Surgical procedure
Rats were anesthetized using 4% isoflurane in O 2 in an induction chamber, mounted in a stereotaxic frame and anesthesia maintained with 2% to 3% isoflurane. Ten microliters of 100 mM AbO was injected into the left lateral ventricle using Bregman coordinates, H-0.8, Tr-1.5, V-4.5, at a flow rate of 2.5 mL/minutes (total administered 5 10 mmol
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). Surgery date was defined as day 0. Rats were treated with IP injections of vehicle or fasudil at 10 mg/kg twice daily from days 21 to 6. The novel object recognition test was performed on day 7 as previously described [22] . In brief, rats were placed in a 52 ! 52 ! 51 cm PVC arena for 3 minutes with two identical objects
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. Animals were taken out of the box for an intertrial interval of 1 minute, then placed back in the same box for a further 3 minutes with an identical copy of the previous object and a novel object. Both sessions were digitally recorded and the time spent exploring each object scored. The discrimination index was calculated as (novel 2 familiar)/(novel 1 familiar).
Statistical analyses
Statistical analyses were performed in GraphPad or SPSS. Differences in quantitative immunofluorescence, dendritic spine number, and morphology were identified by Student's unpaired t-tests. For comparisons between multiple conditions the main effects and simple effects were probed by one-way or two-way analysis of variance with Tukey's correction for multiple comparisons
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. Error bars represent standard errors of the mean.
Results
Ab drives Dkk1 production
Ab drives Dkk1 expression [4, 16, 23] , and Dkk1 protein levels are raised in the brains of Ab/APP-based mouse models of AD pathology [24] . We extend these observations by showing that increases in both Dkk1 messenger RNA and protein are readily detectable in cultured rodent neurons after treatment with the active portion of Ab, Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , and by soluble AbO within 2 to 3 hours, and within 4 hours by AbO at nanomolar concentrations ( Fig. 1A and B).
Synaptic effects of Ab and Dkk1 are similar
To compare the synaptic effects of Ab and Dkk1 protein, rat cortical neurons (24 DIV) were transfected with eGFP and 48 hours later treated with either 2 mM AbO for 4 hours or with 400 ng/mL recombinant Dkk1 protein for 3 hours. The additional 1 hour given for Ab treatments was to allow time for endogenous Dkk1 expression, thereby rendering the two treatments more comparable. AbO and Dkk1 had potent, significant, and very similar 269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335   336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400 401 403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464  465  466  467  468  469   470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535 effects on dendritic spine linear density ( Fig. 1C and D) . After exposure to either AbO or Dkk1, a small number of immature filopodia-like dendritic spines appear to be spared indicating that Ab-driven spine loss is selectively targeting dendritic spines with established postsynaptic densities, something we are now investigating in more detail.
Ab synaptotoxicity is Dkk1 dependent
Antibody neutralization of Dkk1 blocks Ab-induced synapse loss [16] . To extend this, we knocked down Dkk1 expression in primary cortical neuronal cultures using a previously validated penetrating peptide-coupled small interfering RNA (siRNA) duplex targeting rat Dkk1 with a scrambled form as control Q16 [4] . Assessing synapse number by phalloidin-488 labeling of F-actin puncta in the presence of the control siRNA, 2 mM AbO caused a substantial and significant reduction in synapse number in more than 4 hours. This was significantly blocked in neurons treated with the Dkk1 siRNA ( Fig. 1E and F) , confirming that Dkk1 is required for Ab synaptotoxicity to occur.
Dkk1 synaptotoxicity is Daam1 dependent
Activation of the Wnt-PCP/RhoA/ROCK pathway requires an interaction between Disheveled and Daam1 or Daam2 (Fig. 2A) . The only known role of Daam1 and Daam2 is that within the Wnt-PCP pathway [25] [26] [27] . To determine if Dkk1-driven synapse loss is Wnt-PCP dependent we individually knocked down DAAM1 and DAAM2 in rat primary cortical cultures using penetrating siRNA duplexes against each. Western blotting of treated cultures demonstrates that only Daam1 is expressed at detectable levels in these cells and that the DAAM1 siRNA potently reduced Daam1 protein expression (Fig. 2B) . Daam1 is the predominant neuronal isoform [28] . Using DAAM2si as a control, 24 DIV cultures were treated with each siRNA for 48 hours and subsequently with recombinant Dkk1 protein (400 ng/mL) or vehicle for 3 hours, fixed and synapse number again assessed by counting of phalloidin-labeled F-actin puncta. Neither siRNA significantly affected puncta count compared with untreated control subjects, Dkk1 substantially reduced puncta after DAAM2 siRNA treatment but had no effect after DAAM1 siRNA treatment (Fig. 2C and  D) . Consistent with this observation the overexpression of Daam1 reduces the synapse number in hippocampal neurons in a Rho-dependent fashion [28] , whereas Ab has been shown to increase the expression levels of DAAM1 in human neuroblastoma cells [29] .
3.5. Ab-driven, Dkk1-dependent spine loss is mediated by RhoA/ROCK Downstream of Daam Wnt-PCP regulates actin cytoskeletal dynamics through RhoA and ROCK [30, 31] (Fig. 3A and B) . Together with Figs. 1C-G and 2C and D these data provide strong evidence that Ab synaptotoxicity is dependent on Dkk1-driven activation of a Wnt-PCP/Daam1/RhoA/ROCK pathway Q17 .
Dkk1 drives GluA1 and PSD-95 relocation
Acute Ab exposure causes a reduction in synaptic transmission through the internalization of AMPA receptors [32, 33] , whereas Dkk1 has been suggested to cause a removal of PSD-95 from synapses Q18 [16] . However, whether acute exposure to Dkk1 drives the removal of PSD-95 away from dendritic spines and the internalization of AMPA receptors is not known. To investigate this and determine whether effects on PSD-95 and GluA1-containing AMPA receptors could also be blocked by ROCK inhibition, 26 DIV eGFP-expressing cortical neurons were pretreated with Y-27632 or vehicle and subsequently by Dkk1 for 3 hours. After fixation and immunolabeling for PSD-95 and GluA1, confocal imaging revealed that Dkk1 treatment causes a significant reduction in the total number of PSD-95 positive puncta, with significantly fewer PSD-95 positive spines, although concurrently increasing PSD-95 immunoreactive puncta within dendrites. These effects were blocked by Y-27632 ( Fig. 3C and D) . Dkk1 did not effect the total level of GluA1 puncta but did similarly reduce the number of GluA1 positive spines and increase GluA1 immunolabeling within the dendritic shaft, which was again blocked by Y-27632 ( Fig. 3C and E) . Dkk1 then, as with 400 ng/mL Dkk1, fixed, imaged by confocal microscopy, and dendritic spine density and morphology assessed. Both treatments resulted in a significant reduction in dendritic spine linear density (dsld), quantified in (D) (scale bar 5 5 mM). Dsld/10 mm: control, 5.8 6 0.41; AbO, 3.7 6 0.34; Dkk1, 3.5 6 0.31; P , .001 for all treatments. (E) Examination of average dendritic spine area revealed that AbO and Dkk1 cause a significant reduction in spine area (per mm 2 ): control, 0.85 6 0.027; AbO, 0.71 6 0.037; Dkk1, 0.66 6 0.013; P , .01 or P , .001. (F and G) Similar cultures were treated overnight with siDkk1 RNA duplex, or a scrambled version as control, each linked to the Pen-1 peptide. Next day cells were treated with 3 mM AbO for 4 hours, fixed, and fluorescently labeled with phalloidin-488, imaged (F), and F-actin labeled puncta quantified (G) (scale bar 5 50 mM). In all these significance was determined by ANOVA and Tukey's post hoc t-test. Error bars indicate the standard error of the mean. Abbreviations: Ab, amyloid beta; ANOVA, analysis of variance; DIV, days in vitro; mRNA, messenger RNA. 537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581  582  583  584  585  586  587  588  589  590  591  592  593  594 does Ab, induces the removal of PSD-95 and GluA1 proteins from synapses and promotes their trafficking into dendrites. This also confirms that Dkk1-induced dendritic spine loss is concomitant with a loss of synapses via a RhoA/ROCK-dependent mechanism.
Ab and Dkk1-induced spine withdrawal are blocked by fasudil
To confirm that effects of Y-27632 (hexane carboxamide) are via ROCK we selected a second structurally dissimilar ROCK inhibitor, fasudil (an isoquinoline), one of only two ROCK inhibitors approved for use in man Q19 [34] . eGFP expressing cortical cultures were pretreated with 5 mM fasudil or vehicle for 30 minutes and subsequently with either 2 mM AbO or 400 ng/mL Dkk1 recombinant protein, fixed, and imaged by confocal microscopy. Fasudil alone, like Y-27632, had a little effect on spine density. AbO and Dkk1 both significantly reduced spine number and the effects of each were again blocked by fasudil ( Fig. 4A and B) . These data support our contention that the synaptic effects of both Ab and Dkk1 are dependent on the Wnt-PCP/RhoA/ROCK pathway and substantiate the synaptoprotective properties only very recently attributed to fasudil [35] .
Fasudil rescues Ab-driven cognitive deficits
Because fasudil has clinical approval and protects against Ab synaptotoxicity make it a promising candidate for repositioning in AD. To further assess its usefulness we examined its ability to protect against AbO-induced cognitive impairment in vivo using a novel acute rat model [36] . Despite the predicted low central nervous system penetrance of fasudil [37] , both it [38] and its active metabolite hydroxyfasudil [39] appear to be centrally active after peripheral administration
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. Given the paucity of data concerning brain availability of either compound and to inform on dosing for in vivo experimentation we evaluated brain penetrance of fasudil and hydroxyfasudil. Each was administered at a range of doses intraperitoneally to CD1 mice and levels of each were measured in brain and plasma by mass spectrometry. Data obtained demonstrate that fasudil is brain penetrant with a plasma:brain ratio of 8.5% at the 10 mg/kg dose (Fig. 4C ). This figure is better than that of a number of compounds widely used to treat a number of central nervous system web 4C=FPO web 4C=FPO Fig. 3 . Ab and Dkk1 synaptic effects are ROCK dependent. (A and B) Rat primary cortical neurons were transfected with eGFP at 24 DIV and 48 hours later treated with Y27632 or vehicle and 15 minutes later with 2 mM AbO for 4 hours or 400 ng/mL Dkk1 for 3 hours, fixed, and imaged by confocal microscopy for the examination of spine morphology. AbO and Dkk1 caused a significant reduction in dendritic spine linear density. Y2763 alone had no significant effect on spine density but in combination with AbO and Dkk1 blocked the effect of both (scale bar 5 5 mM). (C-E) Rat primary 26 DIV neurons expressing eGFP were treated with Y27632 and Dkk1 all as mentioned in (A). Concurrent with a loss of spine density, Dkk1 caused a significant reduction in total PSD-95 puncta (total PSD-95 density/10 mm: control, 5.5 6 0.34; control 1 Y-27632, 6.2 6 0.55; Dkk1, 4.3 6 0.39; Dkk1 1 Y-27632, 6.6 6 0.43). Interestingly, the number of spines containing PSD-95 was also reduced, with a concurrent increase in the density of dendritic PSD-95, after treatment with Dkk1. This effect was blocked by Y2763 (% spines containing PSD-95: control, 79. disorders such as clozapine (1.1%), haloperidol (1.1%), and diazepam (3.6%) and is similar to that of donepezil, 12.6% [40] , one of the few drugs currently licensed for AD.
On the basis of these data 40 adult female rats of 250 to 300 g body weight were administered fasudil (10 mg/kg) or vehicle (saline) intraperitoneally twice daily for 7 days. After the initial IP injection, all animals underwent surgery on day 1 to receive a single intracranial injection into the left lateral ventricle of either 10 nmol AbO or vehicle in a volume of 10 mL (at 2.5 mL/minutes) resulting in four groups (n 5 10/group). On day 7, all 40 animals were presented with a novel object recognition (NOR) task as previously described [41] . In rats receiving vehicle the single dose of AbO produced a marked and highly significant impairment in NOR performance compared with control subjects. Fasudil alone had no effect on NOR performance but completely rescued performance deficits because of AbO (Fig. 4C) . These data confirm that peripherally administered fasudil is able to block AbO-driven cognitive impairment. Given the supporting evidence presented previously, we propose that fasudil is able to protect against Ab-induced cognitive impairment through its ability to antagonize an Ab activated Dkk1/Wnt-PCP/Daam1/RhoA/ROCK-dependent pathway that drives dendritic spine withdrawal and synapse loss.
Discussion
Opposing roles for the canonical and noncanonical Wnt signaling pathways in synapse homeostasis have been previously recognized, with canonical Wnt promoting synapse formation and stabilization [42] and noncanonical promoting synapse disassembly/pruning [43, 44] . Under normal physiological conditions both pathways likely act in a highly regulated and concerted manner to achieve the appropriate levels of synaptic plasticity and resultant cognitive functioning to occur. Inappropriate levels of Ab . (C) Male CD1 mice were administered fasudil or hydroxyfasudil at 10, 30, and 100 mg/kg, IP and brain and plasma collected 20 minutes after injection. Fasudil and hydroxyfasudil were detected and measured by mass spectrometry. (D and E) Forty young adult female rats were administered 10 mg/kg fasudil, or vehicle, IP, twice daily for 7 days, and given either a single dose of AbO or vehicle, unilaterally, intracerebroventricularly on day 1. On day 7, all animals were presented with a NOR task, schematized in (D). Rats receiving vehicle and AbO showed profound deficit in this task, whereas the performance of rats receiving AbO and fasudil was not different to that of control subjects (E). Abbreviations: Ab, amyloid beta; AbO, Ab 1-42 oligomer; DIV, days in vitro; Dkk1, Dickkopf-1; dsld, dendritic spine linear density; IP, intraperitoneal; NOR, novel object recognition. result in cognitive impairment and memory deficits by disrupting these processes.
Our data demonstrate that Ab-driven synapse withdrawal involves the Dkk1-dependent activation of the Wnt-PCP/RhoA/ROCK pathway. We show that at nanomolar levels, oligomeric forms of Ab regarded to be the most synaptotoxic form of Ab [45, 46] rapidly upregulate neuronal Dkk1 expression, leading to dendritic spine retraction and altered localization of the postsynaptic proteins, PSD-95 and GluA1, in a Daam1-dependent and ROCK-dependent manner.
It has been postulated that Dkk1 alters synapse stability predominantly through antagonism of the canonical Wnt-b-catenin pathway [16] , which will contribute to the process given the role of canonical Wnt in synapse formation and stability [42, 47] . Our data significantly advance on this idea, demonstrating that Dkk1-mediated synapse loss involves the simultaneous and necessary activation of the Wnt-PCP/RhoA/ROCK pathway. This is in line with previous reports specifically pointing to a role of Wnt-PCP in synapse disassembly through core PCP component, Vangl2 [43, 44] .
We previously reported that Ab, through Dkk1, aberrantly activates the JNK/c-Jun arm of Wnt-PCP, and this then drives the expression of genes required for Abinduced neuronal death and increases in tau phosphorylation in vitro and in vivo [4] . Furthermore, we also presented evidence that the signaling pathways most associated with disease in the AD brain are shaped, if not driven by Dkk1/ Wnt-PCP activity [4] . We now argue then that the Abdriven Dkk1-dependent activation of Wnt-PCP underpins several of the key neuropathologic characteristic of AD, including possibly the most fundamental of all, synapse loss. This concept is depicted schematically in Fig. 5 . Given the familial AD gene, APP, the Ab parent molecule, has itself recently been shown to be a modulatory component of the Wnt-PCP coreceptor complex [48] , surely underpins the importance of this pathway in the disease process and indicates that a better understanding of the roles of both Ab and APP in it, will shed further light on the process and our ability to intervene therapeutically to slow it down or prevent it.
Here, not only do we shed new light on these mechanisms but have also identified fasudil, a drug approved for clinical use in Japan and China since 1994 for cerebrovascular vasospasm, as a strong candidate for repositioning/repurposing in AD. We assessed the pharmacodynamics of fasudil and its active metabolite hydroxyfasudil and found that both have good brain penetrance. Because of legal infringements within the pharmaceutical industry fasudil has not received the Food and Drug Administration or European approval Q21 . However, in China it has been used in a small clinical trial in patients with AD in combination with a second vasodilator, nimodipine, and in this study, based on the cognitive assessment, was found to give benefit compared with nimodipine alone [49] .
Given the recent report that ROCK inhibitor Y-27632 can reverse Dkk1-induced synapse loss in vivo [47] and that fasudil is a well tolerated in man [50] , the data we present here concerning its ability to protect against Ab synaptotoxicity, to be brain penetrant, and to protect against Ab-induced cognitive impairment warrant serious assessment of its utility as a much needed treatment for AD.
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RESEARCH IN CONTEXT
1 Systematic review: Several decades of medical research strongly indicate that synapse loss is an early and key event in Alzheimer's disease, and that this is driven by soluble oligomeric forms of the amyloid beta (Ab) peptide. However, the molecular mechanisms underlying Ab synaptotoxicity are not clear, nor has any medication been identified that can halt this.
2 Interpretation: We present strong evidence that Abdriven synapse loss is dependent on a branch of Wnt signaling known as the planar cell polarity pathway. In elucidating this mechanism we found that synapses and cognition in rats are protected from the effects of Ab by a drug in clinical use, fasudil.
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